바이오마커 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of biomarkers Market

The global biomarkers market was valued at USD 86.95 billion in 2025 and is projected to grow to USD 97.5 billion in 2026, reaching USD 217.58 billion by 2034, reflecting a robust CAGR of 12.2% during the forecast period. North America dominated the market in 2025, accounting for a 36.93% share, driven by strong adoption in personalized medicine, significant investments by key players, and advanced healthcare infrastructure.

Biomarkers, or biological markers, are measurable indicators of the biological state of an organ, tissue, or cell. They are critical in disease diagnosis, drug discovery, safety assessment, and biomedical research. Biomarkers are broadly classified based on function, including diagnostic, prognostic, predictive, and other biomarkers, and on biological properties such as genomics, proteomics, and metabolomics.

Market Drivers

The global biomarkers market is primarily driven by the growing diagnostic applications of biomarkers. Biomarkers play an essential role in personalized medicine, helping tailor treatment plans based on a patient's clinical and genetic profile. This is particularly valuable in oncology, where biomarker-guided therapies enhance treatment efficacy. The increasing prevalence of cancer, cardiovascular, and neurodegenerative diseases further fuels demand.

Technological advancements in disease diagnosis, rising investment in biomarker-based drug discovery, and adoption of companion diagnostics are key factors accelerating market growth. For example, Pfizer's Selzentry (Maraviroc) utilizes the Trofile assay biomarker to determine patient response to HIV treatment. Similarly, DiamiR received an award from the Alzheimer's Drug Discovery Foundation in 2019 for research on circulating brain-enriched microRNAs as peripheral biomarkers of neurodegeneration.

Market Restraints

Challenges include high research and development costs, regulatory hurdles, and the need for specialized equipment for biomarker detection. Limited awareness in some emerging markets and the complexity of integrating biomarker data into clinical decision-making may also restrain growth.

Segmentation Analysis

By Indication:

• Oncology dominated the market in 2025 and is expected to hold the largest share in 2026 with 49.44%, driven by rising cancer prevalence and increased use of biomarker-based diagnostics for targeted therapies.
• Cardiology is growing due to the increasing use of biomarkers like troponin for diagnosing cardiovascular diseases.
• Neurology and other indications are emerging segments, fueled by biomarker research in neurodegenerative and rare diseases.

By End User:

• Diagnostics and research laboratories are the largest end-user segment, expected to hold 52.89% of the market in 2026, supported by extensive grants and investment in biomarker development.
• Pharmaceutical & biotechnology companies, hospitals, and specialty clinics represent other end-users driving adoption.

Regional Insights

North America:

• Market size: USD 32.12 billion in 2025, projected USD 35.87 billion in 2026.
• Growth is fueled by strong adoption in personalized medicine, extensive R&D investment, and favorable regulatory approvals. The U.S. market alone is projected to reach USD 31.17 billion in 2026.

Europe:

• Supported by the EU's regulatory framework for in-vitro diagnostics (IVDR), robust clinical research infrastructure, and collaborations between biotech companies and healthcare institutions. The UK market is projected at USD 4.62 billion and Germany at USD 8.02 billion by 2026.

Asia Pacific:

• Market growth is expected to be significant due to the increasing prevalence of cancer and cardiovascular diseases. The Japan market is projected at USD 7.34 billion, China at USD 6.66 billion, and India at USD 2.65 billion by 2026. Rising investments in biomarker-based drug discovery are boosting adoption.

Middle East, Africa, and Latin America:

• Emerging regions are witnessing growth due to the entry of global players, improved healthcare infrastructure, and increased focus on biomarker-based diagnostics.

Key Market Players

The biomarkers market is highly fragmented, led by F. Hoffmann-La Roche Ltd., Abbott, and Thermo Fisher Scientific, Inc., supported by strong R&D and innovation in diagnostic assays. Other notable players include Bio-Rad Laboratories, CENTOGENE N.V., Axon Medchem, Sino Biological Inc., R&D Systems, BioVision Inc., and Myriad RBM.

Recent Developments:

• January 2025: Launch of AI-engineered designer proteins for regenerative medicine.
• February 2025: Expansion of RNAscope(TM) probe portfolio for biomarker validation.
• November 2024: Achieved IVDR certification for R&D Systems hematology controls.
• May 2023: FDA clearance for B*R*A*H*M*S PlGF plus KRYPTOR immunoassays.

Conclusion

The biomarkers market is set for significant growth, from USD 86.95 billion in 2025 to USD 217.58 billion by 2034, fueled by the increasing adoption of personalized medicine, advancements in diagnostics, and the rising prevalence of chronic diseases. Strong investments in R&D, the introduction of novel biomarkers, and collaborations between biotech companies are expected to further drive market expansion across regions, particularly in North America and Asia Pacific.

Segmentation By Indication

• Oncology
• Cardiology
• Neurology
• Others

By End User

• Pharmaceutical & Biotechnology Companies
• Diagnostics & Research Laboratories
• Hospitals & Specialty Clinics
• Others

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. New Product Launches, by Key Market Players
• 4.2. Prevalence by Disease Indication, By Key Countries/ Region, 2025
• 4.3. Incidence of Cancer, By Key Countries/ Key Region,2025
• 4.4. Key industry Developments - Mergers, Acquisitions and Partnerships
• 4.5. Overview of Biomarkers In Personalized Medicine

5. Global Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Indication
  • 5.2.1. Oncology
  • 5.2.2. Cardiology
  • 5.2.3. Neurology
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Pharmaceutical & Biotechnology Companies
  • 5.3.2. Diagnostics & Research Laboratories
  • 5.3.3. Hospitals & Specialty Clinics
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Indication
  • 6.2.1. Oncology
  • 6.2.2. Cardiology
  • 6.2.3. Neurology
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Pharmaceutical & Biotechnology Companies
  • 6.3.2. Diagnostics & Research Laboratories
  • 6.3.3. Hospitals & Specialty Clinics
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Indication
  • 7.2.1. Oncology
  • 7.2.2. Cardiology
  • 7.2.3. Neurology
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Pharmaceutical & Biotechnology Companies
  • 7.3.2. Diagnostics & Research Laboratories
  • 7.3.3. Hospitals & Specialty Clinics
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Indication
  • 8.2.1. Oncology
  • 8.2.2. Cardiology
  • 8.2.3. Neurology
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Pharmaceutical & Biotechnology Companies
  • 8.3.2. Diagnostics & Research Laboratories
  • 8.3.3. Hospitals & Specialty Clinics
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Indication
  • 9.2.1. Oncology
  • 9.2.2. Cardiology
  • 9.2.3. Neurology
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Pharmaceutical & Biotechnology Companies
  • 9.3.2. Diagnostics & Research Laboratories
  • 9.3.3. Hospitals & Specialty Clinics
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis, Insights and Forecast - By Indication
  • 10.2.1. Oncology
  • 10.2.2. Cardiology
  • 10.2.3. Neurology
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Pharmaceutical & Biotechnology Companies
  • 10.3.2. Diagnostics & Research Laboratories
  • 10.3.3. Hospitals and Specialty Clinics
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.4.1. GCC Countries
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.3.1. F. Hoffmann-La Roche Ltd.
    • 11.3.1.1. Overview,
    • 11.3.1.2. Products & services,
    • 11.3.1.3. SWOT analysis,
    • 11.3.1.4. Recent developments,
    • 11.3.1.5. strategies,
    • 11.3.1.6. financials (based on availability)
  • 11.3.2. Abbott
    • 11.3.2.1. Overview,
    • 11.3.2.2. Products & services,
    • 11.3.2.3. SWOT analysis,
    • 11.3.2.4. Recent developments,
    • 11.3.2.5. strategies,
    • 11.3.2.6. financials (based on availability)
  • 11.3.3. Thermo Fisher Scientific
    • 11.3.3.1. Overview,
    • 11.3.3.2. Products & services,
    • 11.3.3.3. SWOT analysis,
    • 11.3.3.4. Recent developments,
    • 11.3.3.5. strategies,
    • 11.3.3.6. financials (based on availability)
  • 11.3.4. Bio-Rad Laboratories, Inc
    • 11.3.4.1. Overview,
    • 11.3.4.2. Products & services,
    • 11.3.4.3. SWOT analysis,
    • 11.3.4.4. Recent developments,
    • 11.3.4.5. strategies,
    • 11.3.4.6. financials (based on availability)
  • 11.3.5. CENTOGENE N.V.
    • 11.3.5.1. Overview,
    • 11.3.5.2. Products & services,
    • 11.3.5.3. SWOT analysis,
    • 11.3.5.4. Recent developments,
    • 11.3.5.5. strategies,
    • 11.3.5.6. financials (based on availability)
  • 11.3.6. Axon Medchem
    • 11.3.6.1. Overview,
    • 11.3.6.2. Products & services,
    • 11.3.6.3. SWOT analysis,
    • 11.3.6.4. Recent developments,
    • 11.3.6.5. strategies,
    • 11.3.6.6. financials (based on availability)
  • 11.3.7. Sino Biological Inc.
    • 11.3.7.1. Overview,
    • 11.3.7.2. Products & services,
    • 11.3.7.3. SWOT analysis,
    • 11.3.7.4. Recent developments,
    • 11.3.7.5. strategies,
    • 11.3.7.6. financials (based on availability)
  • 11.3.8. R&D System
    • 11.3.8.1. Overview,
    • 11.3.8.2. Products & services,
    • 11.3.8.3. SWOT analysis,
    • 11.3.8.4. Recent developments,
    • 11.3.8.5. strategies,
    • 11.3.8.6. financials (based on availability)
  • 11.3.9. BioVision Inc.
    • 11.3.9.1. Overview,
    • 11.3.9.2. Products & services,
    • 11.3.9.3. SWOT analysis,
    • 11.3.9.4. Recent developments,
    • 11.3.9.5. strategies,
    • 11.3.9.6. financials (based on availability)
  • 11.3.10. Myriad RBM
    • 11.3.10.1. Overview,
    • 11.3.10.2. Products & services,
    • 11.3.10.3. SWOT analysis,
    • 11.3.10.4. Recent developments,
    • 11.3.10.5. strategies,
    • 11.3.10.6. financials (based on availability)
  • 11.3.11. Other Prominent Players
    • 11.3.11.1. Overview,
    • 11.3.11.2. Products & services,
    • 11.3.11.3. SWOT analysis,
    • 11.3.11.4. Recent developments,
    • 11.3.11.5. strategies,
    • 11.3.11.6. financials (based on availability)

12. Strategic Recommendation